荣昌生物(09995.HK)今日盘中大涨5.04%,截至盘中收报84.45港元。引发股价上涨的主要原因是公司与参天制药(中国)有限公司达成了一项重要的授权许可协议。
根据公告，荣昌生物将其自主研发的RC28-E注射液在大中华区(中国、香港、澳门及台湾)以及韩国、泰国、越南等多个亚洲国家的独家开发、生产和商业化权利授予参天中国。作为回报，荣昌生物将获得2.5亿元人民币的首付款，以及最高可达10.45亿元人民币的里程碑付款。此外，公司还将根据授权地区的产品销售额收取高个位数至双位数百分比的梯度销售分成。
RC28-E注射液是荣昌生物自主研发的针对眼部新生血管性疾病的VEGF/FGF双靶标融合蛋白药物。此次合作将显著加快RC28-E的市场准入与患者覆盖，缩短商业化周期，为眼底疾病的治疗提供创新且高效的解决方案。分析人士认为，这笔交易不仅为荣昌生物带来可观的收入，还将利用参天制药在眼科领域的专业优势，加速产品在亚洲市场的推广，对公司未来发展具有积极影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.